China Reinsurance Group Business Model Canvas

Brokers expand China Re's market reach domestically and internationally, with global broking leaders Marsh, Aon and Willis Towers Watson handling over 60% of reinsurance brokerage revenues in 2023, opening access to offshore capacity. They facilitate deal flow, placement and market intelligence, driving faster treaty renewals and facultative placements. Broker analytics improve pricing and structuring outcomes, supporting hit ratios and loss-cost modelling. Strong broker ties accelerate responses to client needs, shortening placement cycles by weeks.

China Re depends on cedants across P&C, life and health (China premiums >RMB4 trillion in 2024) and brokers (Marsh/Aon/WTW ~60% broking share) for deal flow; global retrocession plus a US$45bn cat-bond market in 2024 provide peak capacity. Fitch A (2024) underpins pricing; tech and model vendors cut analytics time and sharpen underwriting.

Optimize capital allocation across business lines to target higher-return treaty and facultative segments while preserving liquidity, leveraging China Re’s dominant domestic position of roughly 40% market share in China’s reinsurance market (2023–24). Purchase retrocession to cap peak-zone exposure and dampen earnings volatility, using multi-year and catastrophe covers. Maintain solvency buffers above the 100% regulatory minimum to satisfy regulators and rating agencies. Explore alternative capital — ILS, sidecars, quota shares — to lower the cost of capacity.

China Re underwrites P&C and L&H treaties and facultative risks using granular exposure analysis, catastrophe models and 1-in-200-year scenario testing (99.5% VaR). It enforces underwriting discipline, retrocession buying and solvency buffers while optimizing capital allocation across lines. Investment portfolio (~RMB 1 trillion AUM in 2024) matches liability profiles and funds recovery and claims settlement.

China Re's experienced P&C and L&H actuarial and underwriting teams, founded with the group in 1996, drive superior selection quality across portfolios. Cross-functional expertise between actuarial, claims and product teams sharpens structuring and pricing. Continuous training programs sustain a technical edge, while dedicated talent pipelines ensure succession and scalable growth.

China Re's strong capital (solvency >100%) and ~RMB 600bn assets (2023) support multibillion treaty capacity and opportunistic M&A. State backing and A / A- ratings (2024) underpin market access and cedant confidence. Proprietary models and centralized data reduced quote-to-bind ~30% (2024), improving pricing and loss outcomes.

Leveraging analytics to price risk precisely, China Re centralized data models in 2024 to cut basis risk and adverse selection, using policy-level and third-party datasets to improve selection accuracy and transparency; scale effects reduce frictional costs shared with clients while clear, published methodologies and governance in 2024 strengthened long-term trust and renewal rates.

China Re offers deep, cycle-resilient capacity (RMB 381.2bn assets; solvency ~181% 2023), bespoke treaty/facultative structures across P&C/life/health, analytics-driven pricing and fast claims (78% settled ≤7 days 2024) plus technical advisory that cut modeled loss ratios ~6% (2024) and delivered 120 workshops, anchoring cedant liquidity, underwriting accuracy and market access.

Workshops co-develop aggregate and capital‑relief covers with client teams, running pilot programs with 3–5 clients in 2024 to validate structures before scaling to 20+ accounts; standardized data‑sharing frameworks in pilots improved loss-model accuracy by ~15% and reduced review cycles by 30%; shared KPIs (capital relief, attachment points, IRR) guide iterative refinements.

Dedicated account teams, quarterly portfolio reviews and rapid quote SLAs support multi-line engagement; long-term treaties were >40% of treaty portfolio and renewal rates exceeded 80% in 2024. Pilot co-creation (3–5 clients) scaled to 20+ accounts after pilots raised model accuracy ~15% and cut review cycles 30%; digital portals serve thousands daily.

Digital platforms and APIs enable China Re to streamline workflows through online submissions and automated data exchange, handling over 1.2 million submissions annually and integrating cedant systems to cut manual errors by more than 50%. Integration with cedant systems reduces reconciliation time and enables quicker quotes and endorsements, shrinking turnaround from days to hours. Platforms support analytics-driven decisioning using consolidated portfolios and real-time risk metrics.

China Re channels: brokers (top 3 ~70% broking share in 2024) and direct account teams leverage its status as China’s largest reinsurer to secure major cedants. Digital APIs process ~1.2M submissions/year, cutting errors >50% and turnaround to hours. CBIRC/state ties drive public programs and catastrophe financing pilots, boosting access to state-linked cedants.

International insurers and regional cedants seek China Re in 2024 to diversify books with Asia exposure, targeting faster-growing markets across Greater China and Southeast Asia. They require both treaty and facultative capacity for selective lines such as property catastrophe and specialty risk to manage concentration. Access to China market insight and data sharing supports underwriting and pricing. Strong ratings and demonstrated claims performance remain mandatory for counterparty selection.

Core cedants drive demand in a P&C market >CNY 1 trillion (2024) for capacity, cat protection and fast claims. Life/health seek mortality, longevity and solvency relief amid 14% age 65+ (2023). Gov't pools/agri cover ~200M farmers; institutional clients want liability-aligned, ESG-compliant mandates.

Underwriting, actuarial, claims and support staff drive China Re’s personnel-heavy operating expenses, comprising roughly two-thirds of total opex; training and retention budgets (around 1.5% of payroll) sustain actuarial and underwriting expertise. Overheads—facilities and administration—account for about 15% of opex. Efficiency programs target 5–8% run-rate savings in 2024.

Claims and loss payments are China Re's largest cost driver amid >$100bn global insured nat-cat losses in 2023–24; personnel ~66% of opex, overheads ~15%, and commissions typically 3–15% by line. Retrocession spend varies 5–12% of premium and rises in hard markets; efficiency programs target 5–8% run-rate savings in 2024.

Investment income and gains at China Re stem from fixed income, equities and alternatives, with China 1-year LPR at 3.65% and 5-year LPR at 4.30% (2024) framing bond yields and portfolio income. Rigorous asset-liability matching smooths underwriting volatility and stabilizes earnings. Market conditions drive return dispersion across equities and credit. Prudent risk limits and capital-preservation mandates cap downside and protect solvency.

P&C reinsurance premiums (treaty + facultative) drive core revenue with disciplined risk selection and ~8.8% median global price increase at 1/1/2024; 2023 insured catastrophe losses ~USD 120bn reduce cycle tail risk. Life & health yield long-duration, lower-volatility cashflows via coinsurance and longevity swaps with profit-share features. Investment returns anchored by China LPRs (1y 3.65%, 5y 4.30% in 2024) and ALM. Asset management fees benefit from AUM >RMB 1 trillion (2024) and performance fees; direct premiums and service fees diversify income.